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We used a baculovirus expression system to express fusion proteins of HCV core, RGD (Arg-Gly-Asp) peptide, and
IFN-α2a fragments in Sf9 cells. Western blotting and electron microscopy demonstrate that HCV core, peptides RGD,
and IFN-α2a fusion proteins assemble into 30 to 40 nm nano-particles (virus-like particles, VLPs). Xenograft assays
show that VLPs greatly reduced tumor volume and weight with regard to a nontreated xenograft. Migration and
invasion results show that VLPs can inhibit the migration and invasion of the breast cancer cells MDA-MB231. This
study will provide theoretical and experimental basis for the establishment of safe and effective tumor-targeted
drug delivery systems and clinical application of VLPs carrying cell interacting cargo.
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According to the World Health Organization (WHO), can-
cer is one of the leading causes of death worldwide (http://
www.who.int/mediacentre/factsheets/fs297/en/index.html).
Cancer control has therefore become a global health
strategic focus. Treatment of malignant tumors traditionally
involves a combination of surgery, radiation therapy, and
chemotherapy. Surgery and radiation therapy are effective
in addressing the local tumor; chemotherapy, however,
carries severe toxicity due to lipid solubility and high
therapeutic doses required for most cancers (>70%)
[1]. With these therapeutic limitations, combination
therapy has received close attention in the recent
years. The addition of interferon (IFN) has become
one of the most common additions to combination
therapies.
In 1957, Isaacs and Lindenman discovered a secreted
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in any medium, provided the original work is preplication in influenza virus-infected chick embryo
cells. They named the secreted factor interferon (IFN)
and further classified the compound as either type I or
II [2]. IFN conveys resistance to virus infection, inhibits
tumor cell growth, and modulates the immune response
of the organism. With such broad activity, IFN has
become one of the most actively explored topics of
immunology, genetics, virology, oncology, and molecular
biology research [3]. Therefore, the development of cancer
treatment programs aimed at tumor-specific molecular
targets has become a focus of intense interest and
research. Integrins are a family of cell adhesion receptors
[4]. These receptors are heterodimeric transmembrane
(TM) proteins containing two non-covalently associated α
and β subunits. Integrins transmit bidirectional signals
across the plasma membrane and regulate many biological
functions, including cell differentiation, migration, growth,
and survival. Integrins also play an important role in
tumor invasion and metastasis [5,6]. Studies have shown
that αvβ3 is highly expressed not only on the cell surface
of osteosarcoma, neuroblastoma, lung cancer, breast
cancer, prostate cancer, bladder cancer, glioblastoma,
invasive melanoma, and other solid tumors but also
on neovascular endothelial cells of all tumor tissue
[7-9]. Studies have demonstrated that RGD peptideen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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the activity of αvβ3 integrin [10-12]. Thus, RGD is not only
effective as a drug for the treatment of tumors but can
also be effective in the targeting of tumor-associated
molecules.
Nano-particles can provide tremendous advantages in
drug and gene therapy [13]. A number of artificial poly-
mers have been investigated extensively to formulate
ideal, biodegradable nano-drug delivery carriers, such as
polylactide, poly-L-lactic acid (PLLA), polycaprolactone
(PCL), and poly(lactide-co-glycolide) (PLGA) [14]. Our
pre-experiment research shows that HCV core protein
can form HCV virus particles via baculovirus expression
system. Virus-like particles (VLPs) are free of the virus
genome and cannot cause infection. VLPs are the same
size as nano-particles and appropriate as drug and gene
therapy vectors [15-17].
In this study, we expressed HCV core, RGD peptide,
and IFN-α2a fusion proteins by baculovirus expression
system. We then have examined the specificity of the
fusion protein binding to tumor cells and analyzed the
effect of these fusion proteins on tumor cell migration
and invasion. We further observed the function of
these fusion proteins in a tumor xenograft mouse
model. This study provides theoretical and experi-
mental basis for the establishment of safe and effect-
ive tumor-targeted drug delivery systems and clinical
application of VLPs.
Methods
Cell lines and viruses
Spodoptera frugiperda IPLB-Sf21-AE colonial isolate 9
(Sf9) cells were cultured at 27°C in Grace’s medium
(Invitrogen, Carlsbad, CA, USA) with a supplement of
10% fetal bovine serum (FBS) (Invitrogen). MDA-MB231
human breast cancer cells, HCT116 human colon cancer
cells, and 293 T human embryonic kidney cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum, 100 U/ml
penicillin G, and 100 μg/ml streptomycin, at 37°C under
5% CO2, provided by Wuhan Institute of Virology, Chinese
Academy of Sciences, China Center for Type Culture
Collection (CCTCC, Wuhan, China).
Reagents
Restriction endonuclease enzyme BamHI, EcoRI, SalI,
nucleic acid molecular weight marker, DNA polymerase
Pfu, DNA Marker, Gel extraction kit, and T4 DNA ligase
were from TaKaRa (Shiga, Japan). Reverse transcriptase
polymerase chain reaction (RT-PCR) and RNA extraction
kits were purchased from Life Technologies Corporation
(Grand Island, NY, USA). HCV core antibody was
purchased from Shenzhen Jingmei Biotechnology
Company (Shenzhen, China). Growth factor reducedMatrigel was purchased from BD Bioscience (San Jose,
CA, USA). Ni-NTA Agarose (25 ml) was purchased from
QIAGEN (Germantown, MD, USA). PureLink RNA kit
and cDNA SuperScript First Strand Synthesis kit were
from TaKaRa. Lipofectamine 2000 was purchased from
Life Technologies Corporation. HRP-conjugated goat
anti-rabbit secondary antibody was obtained from Abcam
(Cambridge, MA, USA). West Pico ECL reagent was from
Pierce (Rockford, IL, USA). Dulbecco’s modified Eagle’s
medium (DMEM) and fetal bovine serum were purchased
from Gibco (Grand Island, NY, USA). Penicillin G and
100 μg/ml streptomycin were purchased from Shanghai
Biotechnology Company (Shanghai, China). DNA primers
were synthesized by Shanghai Sangon Biotechnology
Company (Shanghai, China).
Methods
Expression and purification of RGD-IFN-α2a-core fusion
protein
The complete EGFP gene was amplified by PCR using the
pFastBacDual -EGFP as a template with the primers: 5’-
TAGAATTCATGGTGA GCAAGGGC GAGGAG-3’/ 5’-A
CGCGTCGACTTACTTGTACAGCTCGTC-3 and was
cloned into the SalI and EcoRI sites of pFastBac HTb to pro-
duce pFastBac HTb-EGFP. RGD-IFN-α2a (300)-core (the
PCR product length of IFN-α2a is 300 bp), RGD-core-
IFN-α2a (300), RGD-IFN-α2a-core, and RGD-core-IFN-
α2a fragments were amplified using pMD-RGD-IFN-α2a
(300)-core, pMD-RGD-core-IFN-α2a (300), pMD-RGD-
IFN-α2a-core, pMD-RGD-core-IFN-α2a as templates
and 5’-TAGGATCCATGGTCGTGGCGATTGT-3’ / 5’-TA
GAATTCGGCTGAAGCGGGCACAGT-3’ (RGD-IFN-α2a
(300)-core /RGD-IFN-α2a-core); 5’-TAGGATCCATGT GT
CGTGG CGATTGT-3’/ 5’-CGCGAATTCTTCCTTACTT
CTTAAACTTTCTTG-3’ (RGD-core-IFN-α2a (300)); 5’-TA
GGATCCATGTGTCGTGGCGATTGT-3’ / 5’-CCGGAATT
CGAGTTCAGTGTAGAATTTGT-3’ (RGD-core-IFN-α2a)
and subcloned into the pFastBacHTb-EGFP via BamH1/
EcoRI sites and produced pFastBacHTb-EGFP -RGD-IFN-α2a
(300)-core (pH1), pFastcHTb-EGFP-RGD-core-IFN-α2a (300)
(pH2), pFastBacHTb-EGFP-RGD-IFN-α2a-core (pH3), and
pFastBacHTb-EGFP-RGD-Core-IFN-α2a (pH4). All plasmids
were sequenced by Beijing Genomics Institute. The four
plasmids (pH1, pH2, pH3, and pH4) mediated the inser-
tion of genes into the AcBacmid by Tn7-mediated trans-
position to generate AcH1, AcH2, AcH3, and AcH4
bacmids, respectively (Figure 1A). These recombinant
bacmids were confirmed by PCR and were then intro-
duced by transfection into Sf9 cells to produce the
recombinant proteins His-H1, His-H2, His-H3, and
His-H4. These four fusion proteins were purified
by affinity chromatography using Ni-NTA agarose,
according to according to the manufacturer’s directions
(Qiagen, Carlsbad, CA, USA).
Figure 1 RGD-core-IFN-α2a fusion proteins bind breast cancer cells MDA-MB231 in vitro. (A) Recombinant bacmid constructs, showing the
strategy for insertion of the gene cassettes into the polyhedrin locus of the AcMNPV bacmid. RGD-HCV core was fused with IFN-α2a. Both
cassettes depicted were inserted into the attb site (indicated by the right and left insertion sites, Tn7R and Tn7L) in the polyhedrin locus by
Tn-based transposition and generated the recombinant Bacmid: AcH1, AcH2, AcH3, and AcH4. (B) Identification of pH1 and pH2. M: 1Kb Plus
DNA ladder; pH1 and pH2 samples were digested by BamHI and EcoRI. (C) Identification of pH3 and pH4. M: O’Gene Ruler 1Kb DNA ladder; pH3
and pH4 samples were digested by BamHI and EcoRI. (D) Purification of RGD-core-IFN-α2a fusion protein. M: protein marker; 1: His-H1; 2: His-H2;
3: His-H3; 4: His-H4. The recombinant bacmids AcH1, AcH2, AcH3, and AcH4 were introduced by transfection into Sf9 cells to produce the
recombinant proteins His-H1, His-H2, His-H3, and His-H4. The fusion proteins were purified from the supernatants of cell lysates using Ni-NTA
affinity resin. (E, G) Electron micrograph images and Western blotting result of VLP H1. Purified VLPs were attached onto a carbon-coated grid for
5 min at room temperature. The grid was rinsed with distilled water and stained with 1% phosphotungstic acid for 3 min before air drying on
filter paper. The specimens were viewed using a Tecnai G2 transmission electron microscopy at 75 keV. For Western blot, 10 μg purified VLPs
were separated by SDS-PAGE electrophoresis and subjected to Western blot assay. (F, H) Electron micrograph images and Western blotting result
of VLP H2. (I) RGD-core-IFN-α2a fusion protein bind with breast cancer cells MDA-MB231. Then, 0.2, 0.5, 2, 5, and 10 μM fusion proteins His-H1,
His-H2, His-H3, and His-H4 were co-incubated with MDA-MB231 at 37° under 5% CO2. After 2 h, the cells were washed three times with PBS, and
green fluorescence was observed under the fluorescence microscope. Scale bar = 100 μm.
Li et al. Nanoscale Research Letters 2013, 8:401 Page 3 of 10
http://www.nanoscalereslett.com/content/8/1/401
Li et al. Nanoscale Research Letters 2013, 8:401 Page 4 of 10
http://www.nanoscalereslett.com/content/8/1/401Binding specificity assay
MDA-MB231 human breast cancer cells were cultured
in DMEM supplemented with 10% fetal bovine serum,
100 U/ml penicillin G, and 100 μg/ml streptomycin, at
37°C under 5% CO2. Then, 0.2, 0.5, 2, 5, and 10 μM fu-
sion proteins His-H1, His-H2, His-H3, and His-H4
were co-incubated with MDA-MB231 at 37°C under
5% CO2. After 2 h, the cells were washed three times
with PBS, and green fluorescence was observed under
the fluorescence microscope.
Construction of recombinant baculovirus
pH1, pH2, pH3, and pH4 were digested by BamHI/EcoRI
and were subcloned into pFastBac dual vector (pFBD) that
had been pre-treated with BamHI/EcoRI and produced
pFBD-H1, pFBD-H2, pFBD-H3, and pFBD-H4. The
four donor plasmids (pFBD-H1, pFBD-H2, pFBD-H3,
and pFBD-H4) mediated the insertion of genes into the
AcBacmid by Tn7-mediated transposition to generate
AcFBD-H1, AcFBD-H2, AcFBD-H3, and AcFBD-H4
bacmids, respectively. These recombinant bacmids were
confirmed by PCR and then were introduced by transfec-
tion into Sf9 cells to produce the recombinant viruses
vAcH1, vAcH2, vAcH3, and vAcH4.
Real-time Q-PCR and Western blotting
Total RNA was extracted from cells with PureLink RNA
kit (Life Technologies Corporation). cDNA was synthe-
sized with SuperScript First Strand Synthesis kit
(Invitrogen, Carlsbad, CA, USA) with 0.5 to 1.0 μg RNA
according to the manufacturer’s instructions. Quantita-
tive RT-PCR reactions were carried out using SYBR
Green PCR master mix reagents on an ABI 7500 Fast
Real-Time PCR System (Applied Biosystems, Foster City,
CA, USA). The relative quantification of gene expression
for each sample was analyzed by the ΔCt method. The
following primers were used to amplify HCV core: 5’-
GCC CAC AGG ACG TCA AGT −3’ and 5’- CGC AAC
CCT CAT TGC CAT −3’; 18S rRNA: 5’-ACC TGG
TTG ATC CTG CCA GT-3’ and 5’-CTG ACC GGG
TTG GTT TTG AT-3’.
Cells were harvested at 72 h post-infection (hpi) and
lysed in SDS-PAGE loading buffer. Twenty micrograms
of total protein was separated on a 12% sodium dodecyl
sulfate polyacrylamide gel (SDS-PAGE) by electrophoresis
and subjected to Western blot assay. The proteins were
transferred to a membrane that was blocked in 5% milk
1 h at room temperature and incubated with the anti-
HCV core monoclonal antibody (Jingmei Biotechnology
Company; 1:1000 diluted in 5% milk) overnight at 4°C,
followed by extensively washing with TBST (50 mM
Tris–HCl, pH = 7.4, 150 mM NaCl, 0.1% Tween 20). The
membrane was then incubated with the HRP-conjugated
goat anti-rabbit secondary antibody (Abcam) for 1 h atroom temperature before being developed with West Pico
ECL reagent (Pierce).Purification and identification of virus-like particles
Sf9 cells were infected with BV (Budded Virus) of
recombinant baculovirus at an MOI of 0.1. After
3 days, the cell culture supernatant was collected and
clarified at 2,000 × g for 10 min at 4°C. The supernatant
containing the BV was passed through a 0.45-mm pore-
size filter. The filtrate was pelleted through a 25% (wt/wt)
sucrose cushion in 0.1× Tris-buffered EDTA (TE) (TE:
10 mM Tris/HCl, pH 7.5, and 1.0 mM EDTA) at
100,000 × g for 90 min at 4°C, and resuspended in
0.1× TE. For negative staining, purified VLPs were
attached onto a carbon-coated grid for 5 min at room
temperature. The grid was rinsed with distilled water
and stained with 1% phosphotungstic acid for 3 min
before air drying on a filter paper. The specimens were
visualized using a Tecnai G2 transmission electron
microscope (FEI, Hillsboro, OR, USA) at 75 KeV.Xenografts and animal experiments
Animal experiments were performed following a protocol
approved by the Institutional Animal Committee of
Wenzhou Medical College. Thirty female nude mice
(5 to 6 weeks old) were injected subcutaneously with
1 × 106 MDA-MB231 breast cancer cells into the left
and right mammary glands of each animal. Tumor
size was measured daily or every other day with cali-
pers, and tumor volumes were calculated using the
formula: Volume = (width)2 × length/2. Once tumor
volumes reached 250 mm3, animals were randomized
into three groups (n = 5 animals/group): control, VLP
H1, and VLP H2 (1 mg/kg body weight i.p. daily)
were injected intraperitoneally (i.p.) into the mice.
Mice were monitored daily for signs of toxicity, and
body weight and tumor diameters were measured
three times per week. Mice were euthanized 3 weeks
later, and tumors were weighed.Cell migration assays
MDA-MB231 human breast cancer cells were treated
with trypsin and resuspended in DMEM medium
containing 1% FBS and 10 ng/ml EGF and 10 μM VLP H1
or VLP H2, plated at low densities on glass-bottomed
dishes (MatTek, Ashland, MA, USA) coated with 5 μg/ml
fibronectin and cultured for 3 h in a CO2 incubator.
Cell motility was measured with a Nikon Biostation
IMQ (Nikon Instruments Inc., Melville, NY, USA).
Cell migration was tracked for 6 h; images were
recorded every 10 min. The movement of individual
cells was analyzed with NIS-Elements AR (Nikon).
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One hundred microliters of Matrigel (1:30 dilution in
serum-free DMEM medium) was added to each Transwell
polycarbonate filter (6 mm in diameter, 8 μm in pore size,
Costar, Washington, DC, USA) and incubated with the
filters at 37°C for 6 h. Breast cancer cells MDA-MB231 were
trypsinized and washed three times with DMEM containing
1% FBS. The cells were resuspended in DMEM containing
1% FBS at a density of 5 × 105 cells per milliliter. The cell
suspensions (100 μl) were seeded into the upper chambers,
and 600 μl of DMEM medium containing 10% FBS and
10 μM VLP H1 or VLP H2 was added to the lower
chambers. The cells were allowed to invade for 12 h
in a CO2 incubator, fixed, stained, and quantitated as
described previously [18].
Results
Expression and purification of fusion proteins
RGD-IFN-α2a (300)-core, RGD- core-IFN-α2a(300), RGD-
IFN-α2a-core, and RGD-core-IFN-α2a fragments were
amplified using pMD-RGD-IFN-α2a (300)-core, pMD-
RGD- core-IFN-α2a(300), pMD-RGD-IFN-α2a-core, and
pMD-RGD-core-IFN-α2a as templates and subcloned
into the pFastBacHTb-EGFP via BamH1/EcoRI sites
and produced pFastBacHTb-RGD-IFN-α2a (300)-core
(pH1), pFastBacHTb-RGD-core-IFN-α2a(300) (pH2),
pFastBacHTb-RGD-IFN-α2a-core (pH3), and pFastBacHT
b-RGD-core-IFN-α2a (pH4). The expression vectors pH1,
pH2, pH3, and pH4 were confirmed on an agarose gel after
double digestions with BamHI and EcoRI (Figure 1B,C)
and further confirmed by DNA sequencing. Finally, the
successfully constructed expression vectors pH1, pH2,
pH3, and pH4 mediated the insertion of genes into the
AcBacmid by Tn7-mediated transposition to generate
AcH1, AcH2, AcH3, and AcH4 bacmids, respectively
(Figure 1A). These recombinant bacmids were introduced
by transfection into Sf9 cells to produce the recombinant
proteins His-H1, His-H2, His-H3, and His-H4. The fusion
proteins were purified from the supernatants of cell lysates
using Ni-NTA affinity resin under native conditions.
Intense bands corresponding to the molecular weights
of the expected proteins are shown: 59.4 kDa for His-H1
and His-H2; 71.9 kDa for His-H3 and His-H4; the con-
centration of His-H1 and His-H2 is higher than the
His-H3 and His-H4 (Figure 1D).
Identification of virus-like particles
To identify the impurities in the VLP H1 and VLP H2
preparation after crude purification with successive
sucrose gradients, various analyses were performed.
First, confirmation of protein identity in the VLP prepar-
ation was performed by immunoblotting using HCV
core-specific monoclonal antibodies (Figure 1G,H). In
addition, EM analysis of the protein was performedand revealed spherical VLPs of 30 to 40 nm in size
(Figure 1E,F).
RGD- core-IFN-α2a fusion protein specifically binds with
cancer cell line
RGD (arginine-glycine-aspartic acid) can specifically
bind with αvβ3 integrin, which is highly expressed on the
cancer cell surface. The recombinant RGD- core-IFN-
α2a protein was expressed and purified in Sf9. As
expected, the recombinant RGD- core-IFN-α2a can spe-
cifically bind breast cancer cells MDA-MB231 and colon
cancer cells HCT116 (data not shown) but do not bind
normal cells such as normal human embryonic kidney
cell 293 T. The binding activities of His-H1 and His-H2
are stronger than the activity of His-H3 and His-H4
(Figure 1I). The binding activity with MDA-MB231 in-
creased with fusion protein concentration (from 0.5 to
10 μM). When the protein concentration reached
10 μM, the binding activity was found to be at max cap-
acity (Figure 1I).
Real-time Q-PCR and translational analysis
Transcription of RGD- core-IFN-α2a was examined by
RT-PCR, using total RNA isolated from Sf9 cells infected
with the recombinant virus vAcH1, vAcH2, vAcH3, and
vAcH4. The transcriptional levels of vAcH1 and vAcH2
are higher than the vAcH3 and vAcH4 (Figure 2C). At
the same time, the Western blotting results show that
RGD-core-IFN-α2a expression levels in vAcH1 and
vAcH2 are higher than levels from vAcH3 and vAcH4
(Figure 2D). From the results of binding, transcription,
and translation analysis, we concluded that vAcH1 and
vAcH2 are more effective on cancer cells. We then used
vAcH1 and vAcH2 to analyze the VLP functions.
vAcH1 and vAcH2 inhibit breast cancer cells MDA-MD-231
migration and invasion
IFN-α has an established role in cancer therapy in some
cancer types [19-21]. We set out to examine the role of
VLP H1 and VLP H2 in breast cancer cell migration and
invasion. MDA-MB-231 cells were plated on glass-
bottomed dishes coated with 5 μg/ml fibronectin; we then
add 10 μM purified VLP H1, VLP H2, or PBS (as control)
for 2 h. The migration was determined using time-lapse
cell migration assays. VLP H1 and VLP H2 significantly
reduced the total distance and directionality of cell
migration and strongly inhibited the net distance of
cell migration (Figure 3B,C,D,E,F).
To delineate whether VLP H1 and VLP H2 regulate
the invasion of breast cancer cells, MDA-MB-231 cells
were treated with 10 μM purified VLP H1, VLP H2, or
PBS (as control). The invasion of these cells was mea-
sured by examining the functional capacities of the
cells penetrating through transwell filters coated with
Figure 2 Transcription and expression of HCV core-IFN-α2a recombinant viruses. (A) Identification of pFBD-H1 and pFBD-H2. M: 1Kb Plus
DNA ladder; pFBD-H1 and pFBD-H2 samples were digested by BamHI and EcoRI. (B) Identification of pFBD-H3 and pFBD-H4. M: 1Kb Plus DNA
ladder; pFBD-H3 and pFBD-H4 samples were digested by BamHI and EcoRI. (C) RT-PCR results of HCV core gene in recombination viruses infect
cells. Total RNA was isolated from Sf9 infected with vAcH1, vAcH2, vAcH3, or vAcH4. cDNA was synthesized with SuperScript First Strand
Synthesis kit (Invitrogen) with 0.5 to 1.0 μg RNA according to the manufacturer’s instructions. Quantitative RT-PCR reactions were carried out
using SYBR Green PCR master mix reagents on an ABI 7500 Fast Real-Time PCR System (Applied Biosystems). (D) Expression of HCV core-IFN-α2a
fusion protein in recombinant virus infected cells. M: protein marker. Cells were harvested at 72 h post-infection (hpi) and lysed in SDS-PAGE
loading buffer. Twenty micrograms of total protein was separated by SDS-PAGE and subjected to Western blot assay.
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the invasion of MDA-MB-231 cells (Figure 3A).
VLP H1 and VLP H2 inhibit tumor growth in animals
To evaluate VLP H1 and VLP H2 therapeutic potential,
we determined whether VLP H1 and VLP H2 inhibit
MDA-MB231 tumor xenograft growth in nude mice.
MDA-MB231 cells were implanted in nude mice. Aftertumors had established, mice were treated with 10 mg/kg
of VLP H1 or VLP H2 (6 days per week) by intraperitoneal
injection for 3 weeks. VLP H1 and VLP H2 inhibited
tumor growth, resulting in significantly reduced tumor
volumes (Figure 4C). Indeed, the tumors in VLP H1-
and VLP H2-treated mice were significantly smaller
(Figure 4A), and 10 mg/kg of VLP H1 and VLP H2
decreased the tumor mass by 64.58% and 41.36%,
Figure 3 (See legend on next page.)
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Figure 3 VLP H1 and VLP H2 inhibit breast cancer cell migration and invasion. (A) VLP H1 and VLP H2 inhibited the invasion of MDA-MB-231
cells. Data are presented as mean ± SEM, n = 5. Ctrl vs VLP H1; Ctrl vs VLP H2, p < 0.01. (B) Statistic results of net distance of the cells that treated with
PBS, 10 μM VLP H1 or VLP H2. (C) Statistic results of directionality of the cells that treated with PBS, 10 μM VLP H1 or VLP H2. (D) Statistic results of
total distance of the cells that treated with PBS, 10 μM VLP H1 or VLP H2. (E) Statistic results of velocity of the cells that treated with PBS, 10 μM VLP
H1 or VLP H2. The data are expressed as mean ± SEM of more than 60 cells from at least three independent experiments. Single asterisk (*) denotes
P < 0.05 and double asterisk (**) P < 0.01 compared to control. (F) Migration tracks of 10 MDA-MB-231 cells that treated with PBS, 10 μM VLP H1 or
VLP H2.
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H2 did not decrease mouse body weights (Figure 4D) - a
result consistent with the notion that VLP H1 and VLP
H2 preferably target tumor cells and thus exhibited little
toxicity to the animals. Taken together, we demonstrated
that VLP H1 and VLP H2 inhibited tumor growth in vivo.
Discussion
VLPs are multisubunit self-assembly competent protein
structures with identical or highly related overall struc-
ture to their corresponding native viruses [22]. The term
‘VLP’ has been used to describe a number of biological
objects. Uncharacterized structures with viral morph-
ology that are found in biological samples can include
empty structures of viral origin that are not composed
of nucleic acids, infectious viruses with chemically orFigure 4 VLP H1 and VLP H2 suppressed tumor growth in a xenograft
were injected subcutaneously with 1 × 106 MDA-MB231 breast cancer cells in
measured daily or every other day with calipers, and tumor volumes were cal
had established, mice were treated with 10 mg/kg of VLP H1 or VLP H2 (6 da
inhibited tumor growth (A), reduced mouse weight (B), and tumor volumesgenetically introduced structure modifications and
noninfectious, self-assembled gene products resulting
from the cloning and expression of viral structural
genes in heterologous host systems.
HCV is a member of the Flaviviridae family. Its 9.6-kb
RNA genome carries a long open reading frame. This
frame is co- and post-translationally cleaved by cellular
and viral proteases [23] into structural proteins (core, E1,
and E2) and nonstructural proteins (p7, NS2, NS3, NS4A,
NS4B, NS5A, and NS5B). Core, E1, and E2, the structural
proteins, constitute the major viral components of the
viral particles, while the nonstructural proteins are
required at multiple levels of the virus life cycle, including
viral RNA replication [24] and infectious-particle assembly
[25]. The single open reading frame is located between
two untranslated regions (UTRs), the 5’ UTR and the 3’model of human breast cancer. Female nude mice (5 to 6 weeks old)
to the left and right mammary glands of each animal. Tumor size was
culated using the formula: Volume = (width)2 × length/2. After the tumors
ys per week) by intraperitoneal injection for 3 weeks. VLP H1 and VLP H2
(C) but did not decrease mouse body weights (D).
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RNA translation and replication, respectively [26-28].
Falcon et al. observed the presence of enveloped VLPs
with an average diameter of 65 nm in the cytoplasm
and inside cytoplasmic vesicles in HCV-infected patient
liver tissue. Smaller enveloped VLPs with diameters
ranging from 30 to 55 nm were also localized in the
cytoplasm of hepatocytes. All of these VLPs were
clearly composed of an inner electron-dense core-like
particle surrounded by an envelope. In addition, large
numbers of unenveloped VLPs resembling nucleocapsid-
like structures of 30 nm in diameter were detected mainly
in the cytoplasm and also in the ER membranes [29].
Similarly, Chua et al. constructed HCV virus-like particles
using a recombinant adenovirus containing encoding the
HCV structural proteins (core, E1, and E2) of HCV 77H,
genotype 1a [30].
The baculovirus/insect cell system has been used
extensively for the production of VLPs to study viral
assembly processes in the absence of infectious viruses,
produce antigens for immunization and proteins for
diagnostic assays and for gene transfer [31-34]. In this
study, various fusion proteins of HCV core, peptides
RGD (Arg-Gly-Asp), and IFN-α2a fragments (His-H1,
His-H2, His-H3, and His-H4) were successfully expressed
via the baculovirus expression system and purified by Ni-
NTA agarose. Transcriptional and translational analysis
results show that transcriptional levels and expression
levels of vAcH1 and vAcH2 are higher than the vAcH3
and vAcH4. His-H1, His-H2, His-H3, and His-H4 all can
specifically bind with MDA-MB231. The binding activity
of His-H1 and His-H2 is stronger than His-H3 and
His-H4 (Figure 1E). The binding activity of His-H1
and His-H2 on MDA-MB231 increased with protein
concentration (from 0.5 to 10 μM).
At the same time, HCV core, peptide RGD, and
IFN-α2a fragments were expressed by baculovirus expres-
sion system and assembled into VLPs. Western blotting
results and electron microscopy demonstrate that HCV
core, peptides RGD, and IFN-α2a fusion proteins can form
30- to 40-nm-diameter VLPs (Figure 1E,F). Previous ex-
periments showed that IFN provides resistance to virus in-
fection inhibits tumor cell growth and affects the immune
function. Our migration and invasion data indicated that
VLP H1 and VLP H2 (including IFN-α2a fragments)
significantly inhibit MDA-MB231 cells migration and
invasion (Figure 3C,D,E,F,G,H). At the same time, in vivo
studies showed that VLP H1 and VLP H2 inhibit tumor
growth in animals (Figure 4).
Conclusions
In summary, HCV core, RGD (Arg-Gly-Asp), and
IFN-α2a fusion proteins can specifically bind tumor
cells and self-assemble into 30- to 40-nm-diametervirus-like particles. This interaction can significantly
inhibit migration and invasion of MDA-MB231 cells
and tumor growth in animals. These results will provide
theoretical and experimental basis for the establishment of
safe and effective tumor-targeted drug delivery systems
and the clinical application of nano-drugs.
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